CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Consulting Agreement • August 8th, 2024 • Novavax Inc • Biological products, (no disgnostic substances) • Maryland
THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of May 29, 2024 by and between Novavax, Inc. (“Novavax”), a corporation having its principal office at 700 Quince Orchard Road, Gaithersburg, MD 20878 (“Novavax” or the “Company”) and Filip Dubovsky (“Executive”).
COLLABORATION AND LICENSE AGREEMENT BETWEEN SANOFI PASTEUR INC. AND NOVAVAX, INC. Effective Date: May 10, 2024Collaboration and License Agreement • August 8th, 2024 • Novavax Inc • Biological products, (no disgnostic substances)
SUPPLY AGREEMENT BETWEEN NOVAVAX INC AND SERUM LIFE SCIENCES LIMITEDSupply Agreement • August 8th, 2024 • Novavax Inc • Biological products, (no disgnostic substances)
This Supply Agreement (“Supply Agreement”) is made effective as of May 6, 2024 (“Effective Date”) by and between Novavax, Inc., a Delaware USA corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates, successors and permitted assigns), and Serum Life Sciences Limited, a company duly incorporated having its registered office situated in England and Wales, formerly known as Covicure Holdings Limited having its principal office at 15 Grosvenor Street, London, United Kingdom W1K 4QZ (“SLS”). Novavax and SLS may each be referred to herein individually as a “Party” and collectively as the “Parties.”
